Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fumikazu Yamazaki has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drug Survival of Systemic Therapies for Psoriasis in the Western Japan Psoriasis Registry: 2024 Update

    by Noriko Tsuruta, Tetsuji Yanase, Eri Katayama, Chika Ohata, Takuya Miyagi, Kentaro Yonekura, Fumikazu Yamazaki, Kanami Saito, Yuko Higashi, Kazunari Sugita, et al.

    Drug survival is a useful composite measure reflecting treatment effectiveness, safety, convenience, and patient satisfaction in routine clinical practice. The Western Japan Psoriasis Registry (WJPR) is a prospective multicenter observational registry involving 34 dermatology centers in western Japan that continuously collects real‐world data on systemic therapies for patients with psoriasis. Yanase et al. previously reported drug survival in 1674 treatment episodes initiated between 2010 and 2020 within the WJPR; however, large‐scale real‐world data including recently introduced agents remain limited. We analyzed the drug survival of systemic therapies using data from 2251 patients and 4002 treatment episodes recorded in the WJPR between 2018 and 2024. Drug survival was assessed using the Kaplan–Meier method, and analyses were performed overall and stratified according to body mass index (BMI), psoriatic arthritis (PsA), previous biologic exposure, and sex. Multivariable Cox proportional hazards analyses were also performed for drugs with approved indications for PsA. Drug survival differed among treatments, with risankizumab demonstrating the most favorable persistence throughout the observation period, while guselkumab and ixekizumab also showed favorable drug survival. No significant differences in drug survival were observed according to BMI category. However, drug survival tended to be lower overall in patients with PsA, biologic‐experienced patients, and women. Among patients with PsA, bimekizumab maintained relatively favorable drug survival despite the generally lower treatment persistence observed in this subgroup. Multivariable analyses identified previous biologic exposure as the most consistent predictor of treatment discontinuation, whereas BMI was not independently associated with drug survival in any analyzed drug.

  • Open Access

    Cutaneous Squamous Cell Carcinoma in the Sacral Region With Regression Attributed to an Abscopal Effect Induced by Nivolumab and Radiotherapy: A Case Report

    by Tomomichi Shimizu, Akio Kondoh, Hinako Chiba, Shinpei Hamasaki, Sho Arai, Tomomi Inomata, Ayako Hirota, Fumikazu Yamazaki, Tomotaka Mabuchi

    A 78‐year‐old Japanese man with a scar‐like sacral lesion was referred to our hospital due to a red tumor that had developed in the region. Pathological examination of a partial skin biopsy revealed cutaneous SCC. The SCC was regarded as “a Marjolin ulcer” because the tumor developed on a chronic scar. After his first surgery, the tumor had recurred in his sacral region. He underwent a second surgical procedure; however, metastases developed in his inguinal lymph nodes. He was started on nivolumab therapy for four cycles; however, he developed local recurrence in the sacral region. He subsequently underwent local radiotherapy to the recurrent sacral lesion. After completion of local RT, nivolumab was continued for two additional cycles. Two months after his RT, his lymph node metastases surprisingly regressed, although direct radiation was not administered to his inguinal lymph nodes. The present case represents the first reported instance of cutaneous SCC (Marjolin ulcer) in the sacral region treated with nivolumab and RT in which an abscopal effect was observed.

  • A Case of Anti‐ SRP Antibody‐Positive Necrotizing Myopathy That Initially Presented With Raynaud's Phenomenon and a Digital Ulcer

    by Tomomichi Shimizu, Fumikazu Yamazaki, Akio Kondoh, Eimi Kato, Atsushi Mizuma, Eiichiro Nagata, Tomotaka Mabuchi

  • Circulating CD31 and resistin levels reflect different stages of coronary atherosclerosis in patients with psoriasis

    by Trang Nguyen‐Mai Huynh, Fumikazu Yamazaki, Robert J. Konrad, Yumiko Nishikawa, Akihiro Tanaka, Yonsu Son, Yoshio Ozaki, Kazuya Takehana, Hideaki Tanizaki

    Psoriasis is a skin disease with a complicated pathophysiology that includes an extensive inflammatory cytokine network. Nevertheless, the relationship between psoriasis severity, cytokine levels, and coronary artery atherosclerosis remains poorly understood. Our aim was to find serum markers as potential candidates for cardiovascular disease (CVD) risk monitoring in patients with psoriasis. Therefore, we examined coronary artery atherosclerosis via coronary computed tomography angiography (CCTA), serum cytokine levels via multiple immunoassays, and the patients' psoriasis state. Our findings reveal for the first time that the mainstream psoriasis cytokines interleukin 17A (IL‐17A), IL‐19, and IL‐36 in the sera of Japanese patients with psoriasis showed a linear regression association with the Psoriasis Area and Severity Index score. Furthermore, the serum level of IL‐19 was remarkably correlated to T h2 ‐related serum cytokines such as IL‐4 and IL‐17E. When we investigated potential markers to monitor CVD in patients with psoriasis, circulating cluster of differentiation 31 (CD31) and resistin, but not psoriasis‐related cytokines, were expressed differently at each stage of coronary atherosclerosis by CCTA. CD31 and resistin levels rose dramatically in individuals with psoriasis vulgaris (PV) and noncalcified atherosclerosis. In contrast, CD31 was negatively correlated with the coronary artery calcification score (CACS) in patients with PV, whereas resistin was inversely correlated with CACS in patients with psoriatic arthritis. In conclusion, the axis of IL‐17A, IL‐19, and IL‐36 remains associated with the severity of psoriasis during the chronic phase of the disease, regardless of the application of topical or systemic treatment. Monitoring the levels of these cytokines can accurately determine the severity of skin inflammation. Resistin and CD31 are linked to coronary artery lesions and might be good candidates for tracking the progression of coronary atherosclerosis in patients with psoriasis.


  • Clinical characteristics of patients with psoriasis with family history: A multicenter observational study

    by Chika Ohata, Hisataka Anezaki, Sakae Kaneko, Fusako Okazaki, Kotaro Ito, Yuki Matsuzaka, Satoko Kikuchi, Yuta Koike, Hiroyuki Murota, Takuya Miyagi, et al.

    Previous studies on family history of psoriasis showed that patients with a family history have an earlier onset of the disease, but such studies in Japan are still limited. To elucidate the characteristics of patients with familial psoriasis, we studied the family history of patients with psoriasis using the West Japan Psoriasis Registry, a multi‐institutional registry operated by 26 facilities in the western part of Japan, including university hospitals, community hospitals, and clinics. This study enrolled 1847 patients registered between September 2019 and December 2021, with 199 (10.8%) having a family history of psoriasis. Patients with a family history of psoriasis had significantly earlier onset of the disease than those without a family history. Furthermore, patients with a family history of psoriasis had significantly longer disease duration. Psoriatic arthritis (PsA) was significantly more common in patients with a family history (69/199, 34.7%) than in those without a family history (439/1648, 26.6%) (adjusted P = 0.023). A subanalysis of patients with PsA revealed a significant difference in the patient global assessment (PaGA) score in Fisher's exact test and adjusted test. The numbers of patients with PaGA 0/1 were 29 (43.3%) and 172 (39.9%) in patients with PsA with and without family history of psoriasis, respectively, whereas the numbers of patients with PaGA 3/4 were 13 (19.4%) and 145 (33.6%) in patients with PsA with and without family history of psoriasis, respectively. Other disease severity variables did not show a difference between the two groups. Our findings suggest that genetics play a larger role in the development of PsA than in the development of psoriasis vulgaris. Most cases of PsA occur in patients who already have psoriasis, therefore dermatologists should pay attention to joint symptoms, especially in patients with psoriasis who have a family history of psoriasis.


  • Open Access

    The Correlation between the Vascular Calcification Score of the Coronary Artery and the Abdominal Aorta in Patients with Psoriasis

    by Trang Nguyen-Mai Huynh, Fumikazu Yamazaki, Izumi Kishimoto, Akihiro Tanaka, Yonsu Son, Yoshio Ozaki, Kazuya Takehana, Hideaki Tanizaki

    Psoriasis is known as an independent risk factor for cardiovascular disease due to its chronic inflammation. Studies have been conducted to evaluate the progress of atherosclerotic plaques in psoriasis. However, inadequate efforts have been made to clarify the relationship between atherosclerosis progress in coronary arteries and other important blood vessels. For that reason, we investigated the correlation and development of the coronary artery calcification score (CACS) and the abdominal aortic calcification score (AACS) during a follow-up examination. Eighty-three patients with psoriasis underwent coronary computed tomography angiography (CCTA) for total CACS and abdominal computed tomography (AbCT) for total AACS. PASI score, other clinical features, and blood samples were collected at the same time. The patients’ medical histories were also retrieved for further analysis. Linear regression was used to analyze the CACS and AACS associations. There was a moderate correlation between CACS and AACS, while both calcification scores relatively reflected the coronary plaque number, coronary stenosis number, and stenosis severity observed with CCTA. Both calcification scores were independent of the PASI score. However, a significantly higher CACS was found in psoriatic arthritis, whereas no similar phenomenon was recorded for AACS. To conclude, both CACS and AACS might be potential alternative tests to predict the presence of coronary lesions as confirmed by CCTA.


  • Open Access

    Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study

    by Masaru Honma, Yasumasa Kanai, Kenta Murotani, Kei Ito, Chika Ohata, Fumikazu Yamazaki, Hidehisa Saeki, Mariko Seishima, Yoko Mizutani, Hiroki Kitabayashi, et al.

    Itching and skin pain are bothersome symptoms of psoriasis, but evidence is limited regarding the treatment effectiveness on these symptoms in daily clinical settings. We assessed the changes in the levels of itching and skin pain after brodalumab treatment in Japanese patients with psoriasis using patient‐reported outcomes (PROs). Patients with psoriasis who have inadequate response to existing treatments were enrolled in the single‐arm, open‐label, multicenter, prospective ProLOGUE study and received brodalumab 210 mg subcutaneously in daily clinical practice. Psoriasis Area and Severity Index (PASI) and PRO assessments were performed at baseline and weeks 12 and 48. Seventy‐three patients (men, 82.2%; median age, 54.0 years) were enrolled. The Itch Numeric Rating Scale (NRS; p < 0.0001 at weeks 12 and 48) and Skin Pain NRS (week 12, p = 0.0004; week 48, p < 0.0001) scores significantly decreased from baseline. The Itch NRS score was significantly higher in patients with a Dermatology Life Quality Index (DLQI) score of ≥2 (vs. 0/1; p < 0.0001 at weeks 12 and 48) and in patients with a Treatment Satisfaction Questionnaire for Medication‐9 (TSQM‐9) global satisfaction domain score of ≤70% (vs. >70%; week 12, p = 0.0120; week 48, p = 0.0348). The Itch NRS score cutoff value for achieving a PASI score of ≤2, DLQI score of 0/1, and TSQM‐9 global satisfaction domain score of >70% was 1 at week 12 and 0 at week 48. Brodalumab treatment was associated with improvement in itching and skin pain in Japanese patients with psoriasis. An Itch NRS score of 0 can be a long‐term treatment goal for psoriasis (Japan Registry of Clinical Trials identifier: jRCTs031180037).


  • A case of palisaded neutrophilic and granulomatous dermatitis associated with systemic lupus erythematosus presenting with pustules

    by Aki Tajima, Fumikazu Yamazaki, Trang Nguyen Mai Huynh, Ikuko Ueda‐Hayakawa, Izumi Kishimoto, Shizu Itsukage, Noriko Kume, Hideaki Tanizaki

    Palisaded neutrophilic and granulomatous dermatitis (PNGD) is a relatively rare skin disease that is characterized by a reactive granulomatous histopathological pattern and is often associated with systemic autoimmune diseases. We encountered a case of PNGD that presented with pustules, although the prototypical clinical presentation of PNGD is mainly erythema and papules. Here, this rare case of PNGD with pustules is presented and discussed in relation to the relevant literature.


  • Open Access

    Relationship between Psoriasis and Prevalence of Cardiovascular Disease in 88 Japanese Patients

    by Fumikazu Yamazaki, Kazuya Takehana, Akihiro Tanaka, Yonsu Son, Yoshio Ozaki, Hideaki Tanizaki

    Psoriasis is a systemic inflammatory disease known to affect survival in the presence of cerebral or cardiovascular comorbidities. However, no clear guidelines have been defined regarding the extent of vascular lesion testing that should be performed in patients with psoriasis. We therefore performed coronary computed tomography angiography (CCTA) in 88 Japanese patients with psoriasis who visited Kansai Medical University Hospital between 2015 and 2019 and determined the ankle–brachial pressure index (ABI) for 44 of these patients. CCTA abnormalities were found in 39 of the 88 patients, and a need for treatment was identified in 14 patients. The prevalence of cardiovascular lesions in these patients was 15.9%, significantly higher than that in the healthy Japanese population (6.38% according to the Suita Study). In the 44 patients with results for both ABI and CCTA, the rates of CCTA vascular lesions were significantly higher in cases with ABIs indicating hard vessels or above than in cases with supple, normal, or slightly stiff vessels. This is the first report to show a correlation between CCTA and ABI in psoriasis patients. ABI was considered useful as a preliminary test before CCTA. The univariate analysis of the abnormal and normal CCTA groups showed that the prevalence differed significantly among patients with psoriatic arthritis, erythrodermic psoriasis, older age, pre-existing conditions, drinking, and hypertension. The multivariate analysis showed correlations with arthritic or erythrodermic psoriasis.


  • Top Cited Papers
    Open Access

    Psoriasis: Comorbidities

    by Fumikazu Yamazaki

    Psoriasis has long been known as a disease with many complications, but was attributed to diet and obesity. However, in recent years, psoriasis itself has been recognized as a series of systemic inflammatory diseases, and that the cytokines involved can induce a variety of other diseases. Individuals with psoriasis were also found to have higher incidences of cerebral and cardiovascular diseases and a younger age at death compared to healthy individuals. However, no clear guidelines have been defined regarding how much vascular lesion testing should be performed in patients with psoriasis. In this report, I attempt to unravel the objective data on psoriasis and its complications from various reviews and reports, and introduce the impact of biologics, which are currently the main treatment for psoriasis, on cardiac vascular disease.